
CLAIMS

1. Use of an NK-3 receptor antagonist in the manufacture of a medicament for the therapeutic treatment of excess body fat in patients; wherein the NK-3 receptor antagonist is a compound of general formula III:



(III)

and pharmaceutically acceptable solvates thereof, wherein:

R¹ is H, F or methyl;

R¹' is H;

R² is H, F, Cl or methoxy;

R²' is H or F;

R³ is H, F, Cl, methyl, trifluoromethyl, nitrile or **R³** is thiophen-2-yl under the condition that **R⁵** is not methyl;

R⁴ is methyl, ethyl, *n*-propyl, hydroxyethyl, methoxyethyl, trifluoromethyl, difluoromethyl or fluoromethyl;

R⁵ is methyl, ethyl, methoxymethyl, trifluoromethyl, difluoromethyl, fluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl;

X¹ is N and **X²** is S or O; or **X¹** is S and **X²** is N;

represents a single or a double bound depending on **X¹** and **X²**;

stands for the (*R*)-enantiomer or for the racemate of compound of formula III.

2. The use according to claim **1**, under the form of a pharmaceutical composition comprising the NK-3 receptor antagonist and at least one pharmaceutically acceptable vehicle.

3. The use according to claim **1** or claim **2**, for the treatment of patients suffering from pathological excess of body fat.

4. The use according to claim **3**, wherein the patients are selected from individuals suffering from hormonal imbalance; individuals suffering from genetic susceptibility to excess body weight; and individuals where an adipose-specific decrease in weight is deemed to be of therapeutic benefit.

5. The use according to claim **4**, wherein the individuals suffering from hormonal imbalance are selected from women subjected to estrogen-lowering therapies; and women experiencing natural, age-related decreases in estrogen.

6. The use according to claim **4**, wherein the individuals suffering from hormonal imbalance are selected from women that undergo changes in ovarian hormone levels.

7. The use according to claim **4**, wherein the individuals suffering from hormonal imbalance are selected from men subjected to androgen-lowering therapies; and men experiencing natural, age-related decreases in circulating testosterone.

8. The use according to claim **4**, wherein the individuals where an adipose-specific decrease in weight is deemed to be of therapeutic benefit are selected from overweight individuals; individuals receiving medical treatments that are accompanied with weight gain comprising but not limited to hormonal treatment as well as steroids, pain or antipsychotic medications; individuals having inappropriate eating behaviors.


9. The use according to claim **4**, wherein patients are leptin-sensitive patients, preferably leptin sensitive women patients.

10. Use of an NK-3 receptor antagonist in the manufacture of a medicament for the treatment of a leptin-related disease,

wherein the leptin-related disease is selected from metabolic disorders such as diabetes, cardiovascular diseases or metabolic syndrome; lipid regulation disorders such as lipodystrophy, including congenital and acquired lipodystrophy, dyslipidemia, nonalcoholic fatty liver disease, nonalcoholic steatohepatitis or

hyperlipidemia; Congenital Leptin Deficiency; hypothalamic amenorrhea, including exercise-induced hypothalamic amenorrhea; Rabson-Mendenhall syndrome; and osteoporosis; and

wherein the NK-3 receptor antagonist is a compound of general formula III:



(III)

and pharmaceutically acceptable solvates thereof, wherein:

R^1 is H, F or methyl;

R$^{1'}$ is H;

R^2 is H, F, Cl or methoxy;

R$^{2'}$ is H or F;

R^3 is H, F, Cl, methyl, trifluoromethyl, nitrile or **R^3** is thiophen-2-yl under the condition that **R^5** is not methyl;

R^4 is methyl, ethyl, *n*-propyl, hydroxyethyl, methoxyethyl, trifluoromethyl, difluoromethyl or fluoromethyl;

R^5 is methyl, ethyl, methoxymethyl, trifluoromethyl, difluoromethyl, fluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl;

X^1 is N and **X^2** is S or O; or **X^1** is S and **X^2** is N;


⎓ represents a single or a double bound depending on **X^1** and **X^2**;

*⎓ stands for the (*R*)-enantiomer or for the racemate of compound of formula III.

11. The use according to any one of claims **1-10**, wherein the NK-3 receptor antagonist is (R)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone, or a pharmaceutically acceptable solvate thereof.

12. The use according to any one of claims **1-10**, wherein the NK-3 receptor antagonist is (R)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone.

13. A cosmetic treatment method for improving the bodily appearance by stimulating the loss of body fat in a subject, comprising the administration to said subject of a NK-3 receptor antagonist, and optionally the renewal of said administration until the expected cosmetic effect is obtained, wherein the NK-3 receptor antagonist is a compound of general formula III:



(III)

and pharmaceutically acceptable solvates thereof, wherein:

R1 is H, F or methyl;

R1' is H;

R2 is H, F, Cl or methoxy;

R2' is H or F;

R3 is H, F, Cl, methyl, trifluoromethyl, nitrile or **R3** is thiophen-2-yl under the condition that **R5** is not methyl;

R4 is methyl, ethyl, *n*-propyl, hydroxyethyl, methoxyethyl, trifluoromethyl, difluoromethyl or fluoromethyl;

R5 is methyl, ethyl, methoxymethyl, trifluoromethyl, difluoromethyl, fluoromethyl, 1-fluoroethyl, 1,1-difluoroethyl or 2,2,2-trifluoroethyl;

X1 is N and **X2** is S or O; or **X1** is S and **X2** is N;

⎓ represents a single or a double bound depending on **X1** and **X2**;

*⎓ stands for the (*R*)-enantiomer or for the racemate of compound of formula III.

14. The method according to claim 13, wherein the NK-3 receptor antagonist is (R)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone, or a pharmaceutically acceptable solvate thereof.

15. The method according to claim 13, wherein the NK-3 receptor antagonist is (R)-(4-fluorophenyl)(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone.